| |  Online-Ressource |
|---|
| Verfasst von: | Kriegsmann, Katharina [VerfasserIn]  |
|---|
| | Rieger, Michael [VerfasserIn] |
|---|
| | Schwarzbich, Mark-Alexander [VerfasserIn] |
|---|
| | Sitter, Sören [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| | Bruckner, Thomas [VerfasserIn] |
|---|
| | Hensel, Manfred [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Wuchter, Patrick [VerfasserIn] |
|---|
| Titel: | Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma |
|---|
| Verf.angabe: | Katharina Kriegsmann, Michael Rieger, Mark-Alexander Schwarzbich, Sören Sitter, Mark Kriegsmann, Thomas Bruckner, Manfred Hensel, Anthony Dick Ho, Mathias Witzens‐Harig, Patrick Wuchter |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | 25 March 2018 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 29.10.2019 |
|---|
| Titel Quelle: | Enthalten in: European journal of haematology |
|---|
| Ort Quelle: | Oxford : Wiley-Blackwell, 1987 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 101(2018), 1, Seite 12-20 |
|---|
| ISSN Quelle: | 1600-0609 |
|---|
| Abstract: | Objective For more than two decades, high-dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B-cell non-Hodgkin's lymphoma (B-NHL). However, the ideal timing and the collective patient benefits are still being debated. Method We retrospectively analyzed the data of 163 patients with B-NHL who received an HDT protocol followed by ABSCT between 2001 and 2007. Patients were analyzed according to the time point of HDT/ABSCT to compare upfront (directly after induction, n = 72, 44%) versus secondary transplantation (at first relapse, n = 91, 56%). Results The overall response rate was 100% and 94% after upfront and secondary HDT/ABSCT, respectively. No significant differences were found for hematopoietic recovery and toxicity profile. The progression-free survival (PFS) and overall survival (OS) probability were found to be significantly higher in the upfront HDT/ABSCT treatment group (P = .018 and P = .004). In multivariate analysis, upfront HDT/ABSCT and low IPI risk score had a significant beneficial effect on OS (P = .031 and P = .019). Conclusion HDT and ABSCT directly after induction chemotherapy were confirmed to be feasible with high PFS and OS rates. In addition, for patients with relapse after first-line therapy and consecutively poor prognosis, HDT/ABSCT also offers an effective treatment strategy. |
|---|
| DOI: | doi:10.1111/ejh.13064 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1111/ejh.13064 |
|---|
| | Verlag: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13064 |
|---|
| | DOI: https://doi.org/10.1111/ejh.13064 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | non-Hodgkin's lymphoma |
|---|
| | transplantation |
|---|
| K10plus-PPN: | 1680573179 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma / Kriegsmann, Katharina [VerfasserIn]; 25 March 2018 (Online-Ressource)
